EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm

Mary C Clark, Rongze Olivia Lu, Winson S Ho, Matheus Henrique Dias, René Bernards iD, Stephen J Forman

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13687 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2024. Verfasst von Mary C Clark und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA. Hauptthemen laut MEDLINE: Protein Phosphatase 2, Immunotherapy, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade has emerged as a potent new tool in the war on cancer. However, only a subset of cancer patients benefit from this therapeutic modality, sparking a search for combination therapies to increase the fraction of responding patients. We argue here that inhibition of protein phosphatase 2A (PP2A) is a promising approach to increase responses to immune checkpoint blockade and other therapies that rely on the presence of tumor‐reactive T cells. Inhibition of PP2A increases neoantigen expression on tumor cells, activates the cGAS/STING pathway, suppresses regulatory T cells, and increases cytotoxic T cell activation. In preclinical models, inhibition of PP2A synergizes with immune checkpoint blockade and emerging evidence indicates that patients who have tumors with mutations in PP2A respond better to immune checkpoint blockade. Therefore, inhibition of PP2A activity may be an effective way to sensitize cancer cells to immune checkpoint blockade and cell‐based therapies using tumor‐reactive T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Phosphatase 2ImmunotherapyImmune Checkpoint InhibitorsNeoplasmsHumansAnimals

Stichwörter der Autor:innen

PP2ATIL therapycheckpoint inhibitor

Substanzen

Protein Phosphatase 2Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA.
  • Department of Clinical and Translational Project Development, City of Hope Medical Center, Duarte, CA, USA.
  • Department of Neurological Surgery, University of California, San Francisco, CA, USA.
  • Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: René Bernards

Förderung

  • NINDS NIH HHS

Zitieren

APA

Clark, M. C., Lu, R. O., Ho, W. S., Dias, M. H., Bernards, R., & Forman, S. J. (2024). A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm. Molecular Oncology. https://doi.org/10.1002/1878-0261.13687

Vancouver

Clark MC, Lu RO, Ho WS, Dias MH, Bernards R, Forman SJ. A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm. Molecular Oncology. 2024. doi:10.1002/1878-0261.13687

BibTeX
@article{Clark2024,
  author = {Clark, Mary C and Lu, Rongze Olivia and Ho, Winson S and Dias, Matheus Henrique and Bernards, René and Forman, Stephen J},
  title = {A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13687}
}
Kostenlos starten →